Press Releases

Press Releases Aug 01, 2023

ReAlta Doses First Patient in Phase 2...

NORFOLK, Va., August 1, 2023 — ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening...

Read More
Press Releases Jul 27, 2023

Congressman Bobby Scott Tours ReAlta Biotech Research...

Norfolk, VA, June 27, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...

Read More
Press Releases Jun 01, 2023

ReAlta Life Sciences Announces Proof of Mechanism...

Norfolk, VA, June 1, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...

Read More
Press Releases Mar 30, 2023

ReAlta Life Sciences Announces Poster Presentation at...

Presenting proof-of-mechanism clinical trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product...

Read More
Press Releases Jun 01, 2022

ReAlta Life Sciences, Inc. Doses First Patient...

Norfolk, VA, June 1st, 2022 – ReAlta Life Sciences, Inc. (“ReAlta”) a clinical stage, rare disease company addressing life-threatening diseases...

Read More
Press Releases May 10, 2022

Germany’s BfArM Approves ReAlta Life Sciences’ Phase...

Inhaled LPS Challenge Trial to Support Development of RLS-0071 in Severe Asthma   RLS-0071 is ReAlta’s lead dual action complement inhibitor...

Read More
Press Releases Apr 04, 2022

ReAlta Life Sciences’ RLS-0071 Demonstrates Excellent Safety...

RLS-0071 is a dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and...

Read More
Press Releases Mar 30, 2022

FDA Clears ReAlta Life Sciences’ Phase 2...

RLS-0071 is ReAlta’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy...

Read More
Press Releases Mar 04, 2022

ReAlta Life Sciences Announces Poster Presentation at...

Presenting first-in-human trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product candidate...

Read More